ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.The Company unveils brand name for its planned minoxidil hair regrowth product
公司推出其計劃的米諾地爾頭髮再生產品品牌
LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and we expect this process to be completed within a few weeks.
洛杉磯，2023 年 3 月 16 日（全球美通社）-ViaDerma, Inc.（OTC 粉紅色：VDRM）欣然宣布，該公司最近已提交其計劃的米諾地爾頭髮再生產品申請，以獲得 FDA 註冊狀態批准。FDA 註冊過程應該相對較快，我們預計此過程將在幾週內完成。
The company has chosen Nupelo as the brand name for its new hair regrowth product. Nupelo will incorporate ViaDerrma's proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route) in their new hair regrowth product.
該公司選擇 Nupelo 作為其新頭髮再生產品的品牌名稱。Nupelo 將採用 ViaDerrma 專利申請專利的雙載體透皮透皮遞送技術，並在其新的頭髮再生產品中使用米諾地爾（局部路線）。
ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.
ViaDerma 計劃通過多個在線平台（包括其新獲得的域名 nupelo.com）提供 Nupelo 購買。該產品預計將在 2023 年第二季度結束前準備上市，並可在線上購買。
"Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both," said ViaDerma's President & CEO, Dr. Chris Otiko.
「一切都真的很快，順利地融合在一起。由於我們專有的透皮傳送系統具有極高的效果，我們能夠在很短的時間內開發 Nupelo 等新產品。許多其他頭髮產品只能減少脫髮，但在實際再生頭髮方面無效。努珀洛致力於解決這兩個問題，」ViaDerma 的總裁兼首席執行官克里斯·奧蒂科博士說。
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit:
關於維亞德瑪公司
ViaDerma, Inc.（OTC：VDRM）是一家上市的專業製藥公司，致力於將新產品推向市場，並將其創新技術授權給製藥行業在各種治療領域的當前領導者。如需詳細資訊，請造訪：
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
任何對未來表現的預測都是證券法下的「前瞻性聲明」。這些聲明包括在內，讓潛在投資者有機會了解管理層對未來的信念和意見，以便他們可以將這些信念和意見作為評估投資的眾多因素中的一個因素。
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter:
Follow ViaDerma on Facebook:
聯絡資訊：
投資者關係
電郵地址:ir@viaderma.com
電話：
在推特上關注維亞德瑪：
在臉書上關注維亞德瑪：
譯文內容由第三人軟體翻譯。
